Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Latagliata, Roberto  [Clear All Filters]
2023
Tiribelli M, Latagliata R, Breccia M, Capodanno I, Miggiano MCristina, Cavazzini F, Bucelli C, Attolico I, Crescenzi SLeonetti, Russo S, et al. Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML. Cancer. 2023.
2021
Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, et al. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer. 2021.
2020
Mariggiò E, Iori APaola, Micozzi A, Chistolini A, Latagliata R, Berneschi P, Giampaoletti M, La Rocca U, Bruzzese A, Barberi W, et al. Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2020.
Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, et al. RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.
2019
Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2019.
2018
Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leuk Res. 2018;74:86-88.
2016
Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, et al. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget. 2016.